Harnessing The Power of Selective Targeting of Toxic Oligomers to Combat Neurodegenerative Diseases and other Misfolded Protein Diseases

ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. Using our proprietary target discovery engine, we can predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). We have offices in Toronto, Ontario, and Cambridge, Massachusetts.

Leveraging the Key Benefits of Computational Modeling

Our differentiated approach leverages the accuracy of computational modeling to enable the generation of therapeutic antibodies that are highly selective for toxic misfolded proteins and not their normal, physiological forms.

Featured Advantages:

  • Potentially greater efficacy
  • Potential enhanced tolerability and safety
  • Possible improved clinical outcomes

Groundbreaking Science Based on Decades of Research

Our innovative discovery platform is based on the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, and utilizes two complementary techniques to predict DSEs on the molecular surface of toxic oligomers, the key drivers of neurodegenerative diseases.

Learn More About Our Science

Bringing Selective Antibody Therapies Closer to Patients

We are leveraging our patented technology to build a product candidate portfolio of therapeutic antibodies, vaccines, and diagnostics to combat neurodegenerative and other misfolded protein diseases like AD, MSA and ALS. Our therapeutic development programs target the biological cause of these diseases - toxic misfolded forms of proteins.

View Our Pipeline Programs

Led By Distinguished Leaders in Medicine

Our executive team possesses extensive experience in the fields of clinical research and drug development, having held various leadership positions throughout their careers while pioneering the new fields of prion biology and protein misfolding diseases.

Advised by Highly Cited Scientists

Our advisory boards consist of several multidisciplinary specialists in Alzheimer’s and neurodegenerative diseases along with experts in biotech business management, diagnostic product development, and monoclonal antibody design and manufacturing.